How ERP Systems Ensure DSCSA Compliance and Pharmaceutical Traceability

ERP systems support Drug Supply Chain Security Act (DSCSA) compliance by integrating serialization, EPCIS data exchange, package-level traceability, and verification workflows into the operational systems that pharmaceutical companies already use to run their business.

With FDA enforcement now active for manufacturers, wholesale distributors, and large dispensers in 2026, ERP-based compliance is no longer optional infrastructure — it is the operational backbone pharmaceutical trading partners need for pharmaceutical traceability.

What Is DSCSA and Why Does It Matter for Pharma Companies

The Drug Supply Chain Security Act (DSCSA) is the U.S. federal law requiring every prescription drug to be tracked, traced, and verified at the package level — and as of 2025, FDA enforcement has begun for manufacturers, wholesale distributors, and large dispensers.

DSCSA was enacted in 2013 as Title II of the Drug Quality and Security Act, following high-profile drug counterfeiting incidents. The law establishes a nationwide system for pharmaceutical traceability across manufacturers, repackagers, wholesale distributors, dispensers, and third-party logistics providers. Its goal is to protect consumers from counterfeit, stolen, or contaminated prescription drugs. According to the FDA, DSCSA created the framework for interoperable, electronic, package-level tracing.

Understanding Core DSCSA Requirements

DSCSA compliance rests on four operational requirements every trading partner must satisfy:

Serialization and product identification

Every saleable unit of prescription drug must carry a Standardized Numerical Identifier (SNI) combining four GS1 components: the Global Trade Item Number (GTIN), a unique serial number, the lot number, and the expiration date.

GS1 DataMatrix barcodes encode these values at the package level, enabling automated scanning at every handoff and eliminating the data-entry errors that manual lot tracking historically produced.

Interoperable electronic systems

Trading partners must exchange serialized product data electronically using Electronic Product Code Information Services (EPCIS), the FDA-designated format for DSCSA data exchange. Paper Advance Ship Notices and PDF transaction histories are no longer sufficient under enhanced DSCSA requirements. EPCIS messages must travel with the product at every commercial transaction, and every receiving partner must parse them programmatically on arrival.

Traceability across the supply chain

Each prescription drug must be traceable from manufacturer to dispenser at the package level, with complete chain-of-custody data accompanying every transaction. When the FDA issues a traceback request — typically during a product recall or counterfeit investigation — every trading partner must respond with full transaction history within 48 hours or face enforcement action.

Verification and exception handling

Every transaction must be verified against EPCIS data, suspect products must be quarantined and investigated, and saleable returns must be verified through the Verification Router Service (VRS) before re-entering inventory. Exception handling cannot lag — a suspect-product backlog stalls outbound flow, triggers FDA scrutiny during routine inspections, and creates reputational risk with downstream trading partners.

How ERP Systems Support DSCSA Compliance

ERP DSCSA compliance depends on a single system of record where serialized product data, trading partner credentials, transaction history, and exception workflows converge into one auditable platform — the distinction between an integrated pharmaceutical traceability ERP and bolt-on serialization tools.

Centralized data management

An integrated pharmaceutical ERP eliminates the data silos that form when serialization, inventory, returns, and reporting live in separate systems. All DSCSA-relevant data — EPCIS messages, lot and serial numbers, Authorized Trading Partner credentials, exception logs, transaction history — sits in one database accessible to every operational function.

End-to-end lot and serial traceability

The ERP captures lot and serial data at receipt, maintains it through every inventory movement — putaway, pick, pack, transfer — and attaches it to outbound shipments and EPCIS output. This creates a continuous audit trail from supplier to customer without manual entry, making any traceability query a single database operation rather than a multi-system reconciliation.

Integration with track-and-trace systems

A DSCSA compliance ERP must integrate with the serialization, verification, and EPCIS providers handling the technical layer — LSPedia, TraceLink, and rfXcel are most commonly used. S2K Pharma’s native integration with LSPedia gives VAI customers a turnkey DSCSA EPCIS ERP integration path, avoiding custom development that delays vendor migrations.

Real-time reporting and audit readiness

An ERP must produce on-demand reports for any product, transaction, or exception event to satisfy FDA traceback requests within the mandated 48-hour window. Six years of transaction data must remain queryable and exportable. The gap between a compliant response and a warning letter is measured in hours, so reporting must run continuously.

Key ERP Features for Pharmaceutical Traceability

Pharmaceutical-specific ERP systems include four feature categories that generic ERPs lack:

Serialization and barcode tracking

The ERP must capture compliant barcodes — GS1 DataMatrix at the package level and GS1-128 for shipping containers. S2K WMS automatically matches received items against EPCIS data, supporting DSCSA serialization ERP workflows.

Lot control

Every inventory transaction must record lot identifiers for traceability and recall execution. The ERP must enforce First Expired, First Out (FEFO) picking logic and automatically quarantine expired or recalled lots before they ship. Configurable rules should support partial-lot holds during suspect-product investigations.

Compliance reporting tools

The ERP must produce DSCSA-required reports — transaction history, transaction information, and transaction statements — without manual. S2K Pharma also supports DEA license management, Controlled Substance Ordering System (CSOS) transactions, and reporting to drug enforcement agencies, covering the parallel regulatory workload pharmaceutical distributors face alongside DSCSA.

Integration with external partners and regulators

The ERP must exchange EPCIS data with upstream and downstream trading partners, query VRS for saleable returns verification, and submit reports to the FDA and DEA through approved channels. Vendors relying on manual file exports will not scale as transaction volume ramps through 2026.

Benefits of Using ERP for DSCSA Compliance

An integrated pharmaceutical ERP delivers four measurable benefits beyond compliance; each tied directly to operational performance.

• Improved supply chain visibility. Real-time visibility into inventory location, lot status, and serialized product movement across every facility and trading partner — a live picture, not a weekly report.

• Reduced compliance risk. Automated verification at receipt, Authorized Trading Partner validation on every transaction, and a continuous audit trail eliminate the manual gaps where ERP pharmaceutical compliance failures most often occur.

• Faster recall execution. When a manufacturer issues a recall, the ERP identifies every affected package across all locations within minutes — a multi-day manual effort becomes a same-day workflow.

• Operational efficiency. Single data entry, automated PO matching, integrated returns processing, and reduced exception handling deliver labor-cost savings that frequently exceed the compliance value of the ERP itself.

Common Challenges Without an ERP System

Pharmaceutical companies without an integrated ERP face four recurring DSCSA compliance challenges that compound operational risk.

• Manual tracking errors. Spreadsheets and disconnected serialization tools introduce data-entry mistakes that surface as DSCSA exceptions during receipt verification or FDA inspection.

• Disconnected systems. When serialization, inventory, and verification live in separate platforms, the systems frequently disagree about what was received, shipped, or quarantined.

• Limited visibility. Without a single source of truth, operations leaders cannot see real-time inventory status, exception backlogs, or compliance gaps until they trigger a problem.

• Compliance risk exposure. Every manual handoff between systems is a potential point of failure under FDA enforcement — and warning letters typically cite inadequate process controls as the root cause.

How to Choose the Right ERP for DSCSA Compliance

Pharmaceutical companies evaluating ERP systems for DSCSA compliance should assess each vendor against three categories of capability — not against generic compliance claims.

Industry-specific functionality

Ask whether the ERP was built for pharmaceutical distribution from the ground up or adapted from a generic platform. Native EPCIS support, VRS querying, and built-in suspect-product workflows mark a purpose-built pharmaceutical ERP — and the right answer for DSCSA compliance software for distributors is pharmaceutical-first architecture, not generic DSCSA ERP software.

Scalability and integrations

The ERP must integrate with established serialization, verification, and EPCIS providers — LSPedia, TraceLink, and rfXcel. Scalability matters because transaction volume rises as wholesaler and distributor networks fully implement DSCSA across 2026, and any vendor unable to demonstrate production-grade EPCIS throughput at reference customers is a risk.

Regulatory support and updates

DSCSA requirements continue to evolve. Choose an ERP vendor with a track record of regulatory updates — VAI has supported DSCSA evolution since the 2019 saleable returns requirement and delivered subsequent EPCIS, ATP, and enforcement-period updates without disruptive re-implementation.

Preparing for DSCSA 2026 and Beyond

DSCSA compliance is not a one-time project—small dispensers have an exemption period through November 27, 2026, after which full compliance is expected, and FDA guidance will continue to evolve as implementation matures.

Future-proofing compliance

Companies should choose an ERP infrastructure built to absorb regulatory updates without system replacement. Cloud-deployed ERPs under active vendor maintenance — such as S2K Pharma — push compliance updates as the FDA issues new guidance, rather than forcing customer-side IT projects. This architecture determines whether the pharmaceutical ERP DSCSA requirements 2026 remain a vendor responsibility or a customer cost.

Adapting to evolving regulations

Emerging requirements include Authorized Trading Partner (ATP) credential tokens, expanded interoperability standards, and tighter exception-handling expectations.

The right ERP partner monitors FDA guidance and translates regulatory changes into platform updates without customer disruption.